Fig.1 Body weight (A) and body weight change (B) of IMQ induced Psoriasis model in hIL17A/hIL17F mice. (n=6).
Test article 1 and test article 2 are from a collaborator.
Fig.2 IMQ induced Psoriasis model in hIL17A/hIL17F mice. (A) ear thickness (B) skin thickness (C) clinical score (n=6).
Test article 1 and test article 2 are from a collaborator. Mean ± SEM. t-test, *P < 0.05, **P < 0.01, ***P < 0.001.
Fig.3 IMQ induced Psoriasis model in hIL17A/hIL17F mice.
At the study endpoint, back skin samples were harvested and stained with H&E. Representative H&E staining images of the back skin from mice and histological changes were quantified using Baker system. Results indicated that Bimekizumab significantly reduced skin lesions in IMQ induced Psoriasis model in hIL17A/hIL17F mice (n=6).
Test article 1 and test article 2 are from a collaborator. Mean ± SEM. t-test, ***P < 0.001.
Fig.4 IMQ induced Psoriasis model in hIL17A/hIL17F mice.
At the study endpoint, back skin samples were harvested and hIL17F was tested by qPCR. Results indicated that Bimekizumab significantly reduced hIL17F expression level in IMQ induced Psoriasis model in hIL17A/hIL17F mice(n=6).
Test article 1 and test article 2 are from a collaborator. Mean ± SEM. t-test, *P < 0.05.
Fig.1 IMQ induced Psoriasis model in Balb/c. (A) body weight and (B) body weight change. *P<0.05, **P<0.01, ***P<0.001 vs G2.
Fig.2 IMQ induced Psoriasis model in Balb/c. (A) ear thickness (B) skin thickness (C) cumulative score of PASI. ***P<0.001, *P<0.05 vs G2.
Fig.3 IMQ induced Psoriasis model in Balb/c. (A) erythema score, (B) skin thickness score and (C) scabby score. ***P<0.001, **P<0.01, *P<0.05 vs G2.
Fig.4 IMQ induced Psoriasis model in Balb/c. (A) spleen weight, (B) spleen index, (C) spleen image and (D) dorsal image on day3. ***P<0.001 vs G2.
Fig.5 IMQ induced Psoriasis model in Balb/c. (A) serum TNF-α, (B) serum IL-23 and (C) serum IL-17A. ***P<0.001, *P<0.05 vs G2.
Fig.6 IMQ induced Psoriasis model in Balb/c. (A) Tnf-α (B) Il-23 (C) Il-17 mRNA expression of skin. (n=5). ***P<0.001, **P<0.01 vs G2.
Fig.7 IMQ induced Psoriasis model in Balb/c. (A) Pathological Score (B) Epidermis thickness (C) typical pathology image. ****P<0.001, **P<0.01 vs G2.
Fig.1 IMQ induced Psoriasis model based on hIL23A mice.
Rat IL-23因子诱导的SD大鼠银屑病模型
Fig.1 rIL23-induced Psoriasis model in SD Rat. (A) Body weight. (B) Body weight change.
Fig.2 rIL23-induced Psoriasis model in SD Rat. (A) Ear thickness. (B) Ear thickness change. (C) PASI score.
Fig.3 Representative photo of rIL23-induced Psoriasis model in SD Rat.
Fig.4 rIL23-induced Psoriasis model in SD Rat. (A) Representative photo of H&E staining. (B) Baker score.
Human IL-23因子诱导的SD大鼠银屑病模型
Fig.1 hIL23-induced Psoriasis model in SD Rat. (A) Body weight. (B) Body weight change.
Fig.2 hIL23-induced Psoriasis model in SD Rat. (A) Ear thickness. (B) Ear thickness change. (C) PASI score.
Fig.3 Representative photo of hIL23-induced Psoriasis model in SD Rat.
Fig.4 hIL23-induced Psoriasis model in SD Rat. (A) Representative photo of H&E staining. (B) Baker score.
Fig.1 Body weight and body weight change among time during study. Body weight and body weight change in anti-IL23 treated imiquimod (IMQ)-induced psoriasis in HO hTL1A/hIL23A/hIL12B mice (n=3-4 /group, 6weeks, male). IMQ treatment induced body weight loss in male hTL1A/hIL23A/hIL12B mice. Risankizumab treatment didn’t alleviate the weight loss.
Fig.2 Psoriasis evaluation among time during study. In vivo efficacy evaluation of anti-IL23 in imiquimod (IMQ)-induced psoriasis in HO hTL1A/hIL23A/hIL12B mice (n=3-4 /group, 6weeks, male). IMQ treatment successfully induced psoriasis-like skin inflammation in female hTL1A/hIL23A/hIL12B mice, characterized by increased elevated PASI scores (including erythema and scaling) over the 7-day observation period. Notably, Risankizumab alleviated IMQ-induced psoriasis.
Fig.3 H&E staining of psoriatic skin lesions in IMQ-induced mice. Representative H&E staining images of skin from the (A) control, (B) IMQ+vehicle, and (C) IMQ+Risankizumab groups. Scale bar=500 µm. (D) Baker score based on HE pathology images (n=3/group, 6 weeks old).
IMQ treatment induced significant psoriasis-like skin thickening and histopathological features, including parakeratosis, spongiosis, dilated capillaries, and lymphocytic infiltration, as observed in the IMQ-treated groups. Risankizumab treatment slightly alleviated these psoriatic symptoms and reduced epidermal thickness, demonstrating its therapeutic effect in this IMQ-induced psoriasis model.
Fig1. In vivo efficacy evaluation of anti-IL23 and anti-IL23/IL12 in imiquimod (IMQ)-induced psoriasis model in hIL23A/hIL12B mice (3-6 mice/group, 6 weeks, female).
IMQ treatment induced body weight loss in female hIL-23A/hIL-12B mice. Neither Risankizumab nor Ustekinumab treatment alleviated this weight loss, with both antibody-treated groups showing final body weight reductions.
Fig2. In vivo efficacy evaluation of anti-IL23 and anti-IL23/IL12 in imiquimod (IMQ)-induced psoriasis model in hIL23A/hIL12B mice (3-6 mice/group, 6 weeks, female).
IMQ treatment successfully induced psoriasis-like skin inflammation in female hIL-23A/hIL-12B mice, characterized by increased skin thickness and elevated PASI scores (including erythema and scaling) over the 7-day observation period. Notably, Risankizumab demonstrated better therapeutic effect than Ustekinumab in lleviating IMQ-induced psoriasis.
Fig3.H&E staining of psoriatic skin lesions in IMQ-induced mice. Compared to the control group (A) , all IMQ-treated groups displayed skin thickening. The IMQ+Vehicle (B) and IMQ+Ustekinumab (D) groups showed progressive and plaque-stage psoriasis symptoms focal parakeratosis, spongiosis, twisted and dilated capillaries (Black), and lymphocytic infiltration in the dermal papillae (Red), whereas the IMQ+Risankizumab group (C) showed reduced epidermal thickness and ameliorated histopathological features. Scale bar = [500] µm.
IMQ treatment induced significant psoriasis-like skin thickening and histopathological features, including parakeratosis, spongiosis, dilated capillaries, and lymphocytic infiltration, as seen in the IMQ induced groups. Comparing to Ustekinumab, Risankizumab treatment significantly alleviated these psoriatic symptoms and reduced epidermal thickness, demonstrating its therapeutic effect in this IMQ-induced psoriasis model.
